Management Team

banner_std

Dr Jenny Harry – Chief Executive Officer

Jenny Harry has 20 years experience in executive management, securing global partnerships, commercialising technologies and raising capital. In her previous role, as CEO and Managing Director of Tyrian Diagnostics (ASX:TDX) Jenny transformed the company from an R&D business to a diagnostics company, and oversaw development of the company’s first diagnostic products through to commercialisation and early revenue generation. Jenny’s corporate experience extends to leading companies in the biotechnology and biopharmaceutical sectors with expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.

Jenny received a PhD in developmental biology from Macquarie University, Sydney, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. In addition to her role as Managing Director at Ondek®, Dr Harry is a non-executive director on several boards, including Chair of QUT Enterprise Holdings Pty Ltd and a non-executive director on the board of Solvanix Pty Ltd.

Dr Barry Marshall – Scientific Director

Dr Marshall is a world authority on Helicobacter pylori. He is the co-discoverer of the H. pylori organism, co-recipient of the 2005 Nobel Prize for Medicine and Physiology as well as numerous other prestigious awards (including the 1995 Lasker Award) and elected a Fellow of the Royal Society in 1999 and US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discoveries have revolutionised the management of peptic ulcer disease and resulted in the cure for peptic ulcers. Related research into a diagnostic leading to patentable technology resulted in the formation of TriMed Distributors Pty Ltd, a successful private company. Dr Marshall is the founder of Ondek®. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.

Dr Friedrich K Mayer – Head of Drug Development

Friedrich Mayer has 45 years experience in the pharmaceutical industry, both in drugs (small molecules and proteins) and vaccines. Starting in the Sandoz Research Institute in Vienna he moved to corporate headquaters in Basel, Switzerland (now Novartis) as Global Project Leader. He built and led multidisciplinary global project teams taking NMEs from research through registration to life cycle management. These included Sandovac® (influenza vaccine), Exoderil®/Naftin® (naftifine: fungal infections), Lamisil® (terbinafine: fungal infections), Elidel® (pimecrolimus: atopic dermatitis), Miacalcin® Nasal Spray (calcitonin-salmon: osteoporosis), Econor® (valnemulin: bacterial and mycoplasma infections in food animals). After retiring from Novartis he worked in small biotechnology firms. Friedrich has extensive experience in the areas of dermatology, infectious diseases (fungal, bacterial, viral and protozoal), gynecology, bone diseases, endocrinology, immunology, wound healing, veterinary medicine and medical devices.

Friedrich holds a Dr.Sc. (chemistry) from the University of Technology in Vienna, Austria and an MBA from INSEAD in Fontainebleau, France.

Dr Alma Fulurija – Head Immunology and Translational Research

Dr Fulurija is an Australian graduate from Perth, attracted back from Switzerland after a successful career in the fields of novel vaccines and immunology. She has a wide variety of experience in vaccine development and immunotherapy including most recently with Cytos Biotechnology, voted Switzerland’s most exciting new biotechnology start-up float in 2005. She has also worked at the WHO Centre for Neonatal Immunology and Vaccinology in Geneva and has collaborated with Novartis and Pfizer on a number of projects. Dr Fulurija’s key expertise lies in in vivo pre-clinical models, as well as clinical and regulatory requirements for Phase I/II clinical trials. Dr Fulurija is Ondek’s Head of Immunology and Translational Research and also holds an Adjunct Senior Lecturer position at the University of Western Australia

Dr Senta Walton – Senior Immunologist

Dr Walton has considerable research experience in the field of immunology with a particular focus on the immune system in the context of chronic infection. She holds a PhD in biology from the Federal Institute of Technology in Zurich, Switzerland. In 2010 she received a research fellowship from the Swiss National Science Foundation to join Professor Barry Marshall’s group and study the human immune responses to H. pylori infection. She was subsequently awarded an NHMRC early career fellowship to continue her work in Australia. Her research projects have focused on how H. pylori infection modulates the host’s immune system through the characterisation of cellular immune responses in vitro and in vivo. Dr Walton joined Ondek in 2016 in the position of Senior Immunologist and has oversight of many of the research activities associated with Ondek’s immunotherapy programme.